Evaluating only RxSaver’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Competition.
Key Events Timeline
FOUNDING
RetailMeNot/Ziff Davis launches RxSaver as prescription price comparison tool targeting uninsured patients.
PRODUCT LAUNCH
RxSaver expands coverage to 70,000 pharmacy locations and adds medication delivery partner integrations.
REGULATORY ACTION
GoodRx IPOs at $12.7B valuation in October 2020, immediately dominating the prescription discount market with $585M raised.
SHUTDOWN
Ziff Davis quietly shuts down RxSaver in early 2021 as GoodRx's market dominance made competition futile.
Full Analysis
Free · no account needed
Documented cause
RxSaver, operated by RetailMeNot parent Ziff Davis, offered prescription price comparison and pharmacy discount tools with a light delivery integration layer. The platform raised no independent VC funding but was a corporate venture. After GoodRx's dominant IPO in October 2020 at a $12.7B valuation, RxSaver could not compete with GoodRx's network of 70,000+ pharmacies and 15M monthly users. Ziff Davis quietly shut down RxSaver in early 2021, ceding the market entirely to GoodRx.
Lesson
“Corporate ventures in winner-take-most markets must out-execute incumbents before a dominant player IPOs.”